福元医药(601089.SH)：氨氯地平贝那普利胶囊获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Amlodipine Benazepril Capsules, indicating a significant step in expanding its product portfolio in the hypertension treatment market [1]. Group 1: Product Approval - The National Medical Products Administration has issued a drug registration certificate for Amlodipine Benazepril Capsules, with the certificate number 2025S02582, allowing the company to commence production [1]. - The capsules contain 5mg of Amlodipine and 10mg of Benazepril, and are intended for patients whose blood pressure is not adequately controlled by either Amlodipine or Benazepril alone [1]. Group 2: Market Context - Amlodipine Benazepril Capsules were originally developed by Novartis and were first approved for sale in the United States in March 1995 [1]. - The original manufacturer’s version of Amlodipine Benazepril Capsules has not yet been launched in China, presenting a potential market opportunity for the company [1].